EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieRandomisierte kontrollierte Studie

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

Kathleen N Moore, Antoine Angelergues, Gottfried E Konecny, Yolanda García, Susana Banerjee, Domenica Lorusso, Jung-Yun Lee, John W Moroney, Nicoletta Colombo, Andrzej Roszak, Jacqueline Tromp, Tashanna Myers und 19 weitere

New England Journal of Medicine · 07.12.2023 · 389 (23) · 2162-2174

DOI: 10.1056/nejmoa2309169 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 07.12.2023. Verfasst von Kathleen N Moore und 30 weiteren Autor:innen. Beteiligte Einrichtung: From the Stephenson Cancer Center Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City (K.N.M.); Groupe Hosp…. Hauptthemen laut MEDLINE: Carcinoma, Ovarian Epithelial, Maytansine, Ovarian Neoplasms. Die Arbeit wurde bisher 532-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: ImmunoGen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Ovarian EpithelialMaytansineOvarian NeoplasmsFemaleHumansAntibodies, Monoclonal, HumanizedImmunoconjugatesFolate Receptor 1Drug Resistance, NeoplasmPlatinum Compounds

Substanzen

Antibodies, Monoclonal, HumanizedImmunoconjugatesMaytansinemirvetuximab soravtansineFOLR1 protein, humanFolate Receptor 1Platinum Compounds

Autor:innen und Institutionen

  • From the Stephenson Cancer Center Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City (K.N.M.); Groupe Hospitalier Diaconesses-Croix Saint Simon, Paris (A.A.), Aix-Marseille Uni…

Förderung

  • ImmunoGen

Zitieren

APA

Moore, K. N., Angelergues, A., Konecny, G. E., García, Y., Banerjee, S., Lorusso, D., Lee, J. Y., Moroney, J. W., Colombo, N., Roszak, A., Tromp, J., Myers, T., Lee, J. W., Beiner, M., Cosgrove, C. M., Cibula, D., Martin, L. P., Sabatier, R., Buscema, J., …, & Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups (2023). Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. New England Journal of Medicine, 389(23), 2162-2174. https://doi.org/10.1056/nejmoa2309169

Vancouver

Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, et al. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. New England Journal of Medicine. 2023;389(23):2162-2174. doi:10.1056/nejmoa2309169

BibTeX
@article{Moore2023,
  author = {Moore, Kathleen N and Angelergues, Antoine and Konecny, Gottfried E and García, Yolanda and Banerjee, Susana and Lorusso, Domenica and Lee, Jung-Yun and Moroney, John W and Colombo, Nicoletta and Roszak, Andrzej and Tromp, Jacqueline and Myers, Tashanna and Lee, Jeong-Won and Beiner, Mario and Cosgrove, Casey M and Cibula, David and Martin, Lainie P and Sabatier, Renaud and Buscema, Joseph and Estévez-García, Purificación and Coffman, Lan and Nicum, Shibani and Duska, Linda R and Pignata, Sandro and Gálvez, Fernando and Wang, Yuemei and Method, Michael and Berkenblit, Anna and Bello Roufai, Diana and Van Gorp, Toon and Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups, Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups},
  title = {Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {23},
  pages = {2162--2174},
  doi = {10.1056/nejmoa2309169}
}
Kostenlos starten →